Detalhe da pesquisa
1.
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.
Diabetes Obes Metab
; 25(3): 805-814, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433713
2.
Pharmacokinetics, mass balance, metabolism, and excretion of the liver-targeted acetyl-CoA carboxylase inhibitor PF-05221304 (clesacostat) in humans.
Xenobiotica
; 52(3): 240-253, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35382680
3.
Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies.
Xenobiotica
; 49(12): 1447-1457, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30747552
4.
Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.
Diabetes Obes Metab
; 20(11): 2608-2616, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29923286
5.
Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.
Pharm Res
; 33(12): 3021-3030, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27620173
6.
Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment.
Drug Metab Dispos
; 43(2): 190-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25384899
7.
Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy.
Clin Transl Sci
; 17(1): e13644, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38108609
8.
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants.
Clin Transl Sci
; 17(2): e13687, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38362827
9.
Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs.
Clin Pharmacol Ther
; 113(5): 1058-1069, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36524426
10.
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19.
Open Forum Infect Dis
; 10(8): ofad355, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37559753
11.
Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Pharm Res
; 29(10): 2860-73, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22638872
12.
Metabolism and Excretion of Nirmatrelvir in Humans Using Quantitative Fluorine Nuclear Magnetic Resonance Spectroscopy: A Novel Approach for Accelerating Drug Development.
Clin Pharmacol Ther
; 112(6): 1201-1206, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35678736
13.
Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug.
Clin Pharmacol Ther
; 112(3): 605-614, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35355249
14.
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Clin Pharmacol Ther
; 112(1): 101-111, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35388471
15.
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
Br J Clin Pharmacol
; 71(3): 429-36, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21284702
16.
Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial.
Med
; 2(7): 800-813.e3, 2021 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35590219
17.
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.
Nat Med
; 27(6): 1079-1087, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34127852
18.
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials.
Nat Med
; 27(10): 1836-1848, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34635855
19.
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction.
Mol Metab
; 48: 101196, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33667726
20.
Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
Drug Metab Dispos
; 38(3): 474-83, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20016053